NCT01288937 - A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2011

Primary Completion Date

October 22, 2014

Study Completion Date

December 23, 2014

Conditions

Idiopathic Peripheral Neuropathy

Interventions

DRUG

Milnacipran

"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"

DRUG

Placebo

Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.

Trial Locations (1)

10032

Columbia University Medical Center, New York